Dong Sung Bio Pharm.Co.,Ltd. (002210.KS)
KRW 3500.0
(-12.17%)
KRW 3500.0
(-12.17%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 3.42 Billion KRW | 3289.8% |
| 2022 | 1.52 Billion KRW | 105.91% |
| 2021 | -1.73 Billion KRW | 6.76% |
| 2020 | -8.14 Billion KRW | 66.04% |
| 2019 | -5.32 Billion KRW | -618.16% |
| 2018 | -3.08 Billion KRW | -64.49% |
| 2017 | 2.64 Billion KRW | 417.09% |
| 2016 | 425.9 Million KRW | -123.58% |
| 2015 | 3.02 Billion KRW | 431.37% |
| 2014 | 37.79 Million KRW | -853.86% |
| 2013 | 163.43 Million KRW | -98.24% |
| 2012 | 7.46 Billion KRW | 35.21% |
| 2011 | 5.25 Billion KRW | 341.75% |
| 2010 | -1.13 Billion KRW | -172.2% |
| 2009 | 3.69 Billion KRW | -38.49% |
| 2008 | 8.45 Billion KRW | 26.74% |
| 2007 | 3.74 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 596.21 Million KRW | 106.92% |
| 2024 Q2 | -1.47 Billion KRW | -264.72% |
| 2023 Q2 | 673.93 Million KRW | -60.65% |
| 2023 Q1 | 1.71 Billion KRW | 384.97% |
| 2023 Q4 | -116.61 Million KRW | -101.05% |
| 2023 FY | - KRW | 3289.8% |
| 2023 Q3 | 11.14 Billion KRW | 1553.97% |
| 2022 Q3 | 1.63 Billion KRW | 236.22% |
| 2022 Q4 | 353.15 Million KRW | -78.43% |
| 2022 FY | - KRW | 105.91% |
| 2022 Q1 | -710.51 Million KRW | 60.81% |
| 2022 Q2 | -1.2 Billion KRW | -69.15% |
| 2021 Q3 | 102.39 Million KRW | -80.72% |
| 2021 Q4 | -1.81 Billion KRW | -1870.61% |
| 2021 Q1 | -489.09 Million KRW | 73.81% |
| 2021 Q2 | 531.12 Million KRW | 208.59% |
| 2021 FY | - KRW | 6.76% |
| 2020 Q1 | -178.82 Million KRW | 94.89% |
| 2020 FY | - KRW | 66.04% |
| 2020 Q2 | 1.93 Billion KRW | 1183.66% |
| 2020 Q3 | -1.3 Billion KRW | -167.36% |
| 2020 Q4 | -1.86 Billion KRW | -43.08% |
| 2019 Q3 | -464.62 Million KRW | -29.12% |
| 2019 Q2 | -359.84 Million KRW | -320.65% |
| 2019 Q1 | 163.07 Million KRW | 125.47% |
| 2019 FY | - KRW | -618.16% |
| 2019 Q4 | -3.5 Billion KRW | -653.86% |
| 2018 FY | - KRW | -64.49% |
| 2018 Q2 | 218.22 Million KRW | -48.75% |
| 2018 Q4 | -640.16 Million KRW | -180.04% |
| 2018 Q1 | 425.79 Million KRW | 150.4% |
| 2018 Q3 | 799.77 Million KRW | 266.49% |
| 2017 FY | - KRW | 417.09% |
| 2017 Q2 | 1.4 Billion KRW | 132.27% |
| 2017 Q1 | 603.08 Million KRW | 505.55% |
| 2017 Q4 | -844.88 Million KRW | -176.54% |
| 2017 Q3 | 1.1 Billion KRW | -21.2% |
| 2016 Q3 | -815.24 Million KRW | -71.19% |
| 2016 FY | - KRW | -123.58% |
| 2016 Q4 | -148.7 Million KRW | 81.76% |
| 2016 Q1 | 726.51 Million KRW | 49.38% |
| 2016 Q2 | -476.21 Million KRW | -165.55% |
| 2015 FY | - KRW | 431.37% |
| 2015 Q4 | 486.36 Million KRW | 213.7% |
| 2015 Q3 | -427.77 Million KRW | -138.24% |
| 2015 Q2 | 1.11 Billion KRW | -39.5% |
| 2015 Q1 | 1.84 Billion KRW | 164.54% |
| 2014 FY | - KRW | -853.86% |
| 2014 Q2 | 537.63 Million KRW | -35.94% |
| 2014 Q4 | -2.86 Billion KRW | -598.6% |
| 2014 Q3 | 574.53 Million KRW | 6.86% |
| 2014 Q1 | 839.24 Million KRW | 140.43% |
| 2013 Q1 | 1.42 Billion KRW | 10.74% |
| 2013 Q2 | 411.14 Million KRW | -71.12% |
| 2013 Q3 | 361.91 Million KRW | -11.97% |
| 2013 FY | - KRW | -98.24% |
| 2013 Q4 | -2.07 Billion KRW | -673.53% |
| 2012 Q4 | 1.28 Billion KRW | 6.55% |
| 2012 Q3 | 1.2 Billion KRW | -53.64% |
| 2012 Q2 | 2.6 Billion KRW | 4.08% |
| 2012 Q1 | 2.5 Billion KRW | 0.0% |
| 2012 FY | - KRW | 35.21% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | - KRW | 341.75% |
| 2011 Q3 | 997.92 Million KRW | -43.34% |
| 2011 Q2 | 1.76 Billion KRW | 0.25% |
| 2011 Q1 | 1.75 Billion KRW | 149.97% |
| 2010 Q3 | 634.05 Million KRW | 115.13% |
| 2010 FY | - KRW | -172.2% |
| 2010 Q4 | -3.51 Billion KRW | -654.52% |
| 2010 Q1 | 481.35 Million KRW | 3386.62% |
| 2010 Q2 | 294.73 Million KRW | -38.77% |
| 2009 Q3 | 841.04 Million KRW | 24.3% |
| 2009 Q1 | 1.41 Billion KRW | 6335.41% |
| 2009 FY | - KRW | -38.49% |
| 2009 Q2 | 676.61 Million KRW | -52.09% |
| 2009 Q4 | -14.64 Million KRW | -101.74% |
| 2008 Q2 | 2.83 Billion KRW | 46.62% |
| 2008 Q1 | 1.93 Billion KRW | 247.44% |
| 2008 FY | - KRW | 26.74% |
| 2008 Q4 | -22.64 Million KRW | -2837.48% |
| 2008 Q3 | -771 Thousand KRW | -100.03% |
| 2007 Q1 | 1.78 Billion KRW | 0.0% |
| 2007 Q4 | -1.31 Billion KRW | -200.33% |
| 2007 FY | - KRW | 0.0% |
| 2007 Q2 | 1.96 Billion KRW | 10.29% |
| 2007 Q3 | 1.3 Billion KRW | -33.51% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | 89.494% |
| Yuhan Corporation | 127.43 Billion KRW | 97.315% |
| Yuhan Corporation | 127.43 Billion KRW | 97.315% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | 29.585% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | 29.585% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | 29.585% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 105.342% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | 71.077% |
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | 97.58% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 96.166% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 96.166% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 96.166% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | 115.774% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | 94.507% |
| HANDOK Inc. | 35.06 Billion KRW | 90.244% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | 89.781% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | 430.027% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | 111.191% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | 106.94% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | 118.52% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | 93.13% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | 55.28% |
| Boryung Corporation | 114.28 Billion KRW | 97.007% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | 74.102% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | 90.662% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | 77.372% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | 77.372% |
| Suheung Co., Ltd. | 77.02 Billion KRW | 95.559% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | 93.777% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | 31.448% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | 90.706% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | 24.422% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 109.229% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 109.229% |
| Korea United Pharm Inc. | 70.78 Billion KRW | 95.167% |
| CKD Bio Corp. | -1.63 Billion KRW | 309.819% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | 97.926% |
| JW Holdings Corporation | 187.88 Billion KRW | 98.179% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | 47.811% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 98.942% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | 90.883% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | 98.794% |
| JW Lifescience Corporation | 50.82 Billion KRW | 93.27% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | 106.678% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | 81.662% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | 90.36% |